LILRA1/CD85i/LIR-6[Biotin], His & Avi, Human
LILRA1/CD85i/LIR-6[Biotin], His & Avi, Human

The purity of LILRA1/CD85i/LIR-6[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC.

LILRA1/CD85i/LIR-6[Biotin], His & Avi, Human

LILRA1/CD85i/LIR-6[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

LILRA1/CD85i/LIR-6[Biotin], His & Avi, Human

LILRA1, also known as CD85i and LIR-6, is an approximately 70 kDa variably glycosylated transmembrane protein that regulates immune cell activation. Mature human LILRA1 consists of a 445 amino acid (aa) extracellular domain (ECD) with 4 Ig-like domains, a 21 aa transmembrane segment, and a 7 aa cytoplasmic tail. LILRA1 may act as receptor for class I MHC antigens.
Z04536
¥123,118.00

Ask us a question
Product Introduction
Species Human
Protein Construction
LILRA1/CD85i/LIR-6 (Pro17-Asn461)
Accession # O75019-1		 His Avi
N-term C-term
Conjugate Biotin
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 0.1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 51.4 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 70-80 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • LILRA1/CD85i/LIR-6[Biotin], His & Avi, Human
    • LILRA1/CD85i/LIR-6[Biotin], His & Avi, Human

    The purity of LILRA1/CD85i/LIR-6[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC.

  • LILRA1/CD85i/LIR-6[Biotin], His & Avi, Human
    • LILRA1/CD85i/LIR-6[Biotin], His & Avi, Human

    LILRA1/CD85i/LIR-6[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background LILRA1, also known as CD85i and LIR-6, is an approximately 70 kDa variably glycosylated transmembrane protein that regulates immune cell activation. Mature human LILRA1 consists of a 445 amino acid (aa) extracellular domain (ECD) with 4 Ig-like domains, a 21 aa transmembrane segment, and a 7 aa cytoplasmic tail. LILRA1 may act as receptor for class I MHC antigens.
Synonyms CD85i; LILRA1; LIR6; LIR-6; LIR6MGC126563

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.